Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

In Brief

This article was originally published in The Tan Sheet

Executive Summary

Pharma vets acquire Nutrition 21 assets; FDA approves Perrigo’s generic Mucinex; Pfizer closes Ferrosan consumer health deal; DEA allows PSE log flexibility; and more OTC drug and nutritional product market news In Brief

You may also be interested in...



Supplement Space Exits: Bankruptcy Traffic Could Accelerate

Gaspari Nutrition, acquired by Allegro Nutrition, sought Chapter 11 protection after its debt load outstripped its revenue outlook. Natrol threw in the towel and filed after federal judges consolidated multiple class action claims accusing the firm of false advertising for its joint relief products.

Supplement Space Exits: Bankruptcy Traffic Could Accelerate

Gaspari Nutrition, acquired by Allegro Nutrition, sought Chapter 11 protection after its debt load outstripped its revenue outlook. Natrol threw in the towel and filed after federal judges consolidated multiple class action claims accusing the firm of false advertising for its joint relief products.

Nutrition 21 Revives Under Leadership Of Former Pharma Exec Satow

Michael Satow, formerly of JDS Pharmaceuticals, tries his hand in the nutritional ingredients space as CEO of Nutrition 21. In a recent interview, Satow discussed his initial impressions of the industry and what potential he sees in a portfolio that includes Chromax chromium picolinate.

Related Content

Topics

Related Companies

Latest News
UsernamePublicRestriction

Register

PS105452

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel